Comorbid Conditions in a Cohort of Inpatients with SARS-CoV-2 and their Association with In-Hospital Mortality During the Early Phases of the Pandemic

1 J. Li et al., “Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes,” J. Med. Virol., vol. 93, no. 3, pp. 1449–1458, Mar. 2021, doi: 10.1002/jmv.26424. Search in Google Scholar

2 M. Scortichini et al., “Excess mortality during the COVID-19 outbreak in Italy: A two-stage interrupted time-series analysis,” Int. J. Epidemiol., vol. 49, no. 6, pp. 1909–1917, 2020, doi: 10.1093/ije/dyaa169. Search in Google Scholar

3 A. Karlinsky and D. Kobak, “The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemic.,” medRxiv Prepr. Serv. Heal. Sci., p. 2021.01.27.21250604, Jan. 2021, doi: 10.1101/2021.01.27.21250604. Search in Google Scholar

4 A. Silverio et al., “Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients,” BMC Cardiovasc. Disord., vol. 21, no. 1, pp. 1–13, 2021, doi: 10.1186/s12872-020-01816-3. Search in Google Scholar

5 B. G. Marin et al., “Predictors of COVID-19 severity: A literature review,” Rev. Med. Virol., vol. 31, no. 1, p. 1, Jan. 2021, doi: 10.1002/RMV.2146. Search in Google Scholar

6 S. L. Harrison, E. Fazio-Eynullayeva, D. A. Lane, P. Underhill, and G. Y. H. Lip, “Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis,” PLoS Med., vol. 17, no. 9, Sep. 2020, doi: 10.1371/JOURNAL.PMED.1003321. Search in Google Scholar

7 F. Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” Lancet, vol. 395, no. 10229, pp. 1054–1062, Mar. 2020, doi: 10.1016/S0140-6736(20)30566-3. Search in Google Scholar

8 Ö. Ergönül et al., “National case fatality rates of the COVID-19 pandemic,” Clin. Microbiol. Infect., vol. 27, no. 1, pp. 118–124, Jan. 2021, doi: 10.1016/j.cmi.2020.09.024. Search in Google Scholar

9 O. Hradsky and A. Komarek, “Demographic and public health characteristics explain large part of variability in COVID-19 mortality across countries,” Eur. J. Public Health, vol. 31, no. 1, pp. 12–16, 2021, doi: 10.1093/eurpub/ckaa226. Search in Google Scholar

10 L. Piroth et al., “Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study,” Lancet. Respir. Med., vol. 9, no. 3, pp. 251–259, Mar. 2021, doi: 10.1016/S2213-2600(20)30527-0. Search in Google Scholar

11 V. De Groot, H. Beckerman, G. J. Lankhorst, and L. M. Bouter, “How to measure comorbidity: A critical review of available methods,” J. Clin. Epidemiol., vol. 56, no. 3, pp. 221–229, Mar. 2003, doi: 10.1016/S0895-4356(02)00585-1. Search in Google Scholar

12 M. Charlson, T. P. Szatrowski, J. Peterson, and J. Gold, “Validation of a combined comorbidity index,” J. Clin. Epidemiol., vol. 47, no. 11, pp. 1245–1251, 1994, doi: 10.1016/0895-4356(94)90129-5. Search in Google Scholar

13 R. A. Kuswardhani, J. Henrina, R. Pranata, M. Lim, S. Lawrensia, and K. Suastika, “Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis,” Diabetes Metab Syndr., vol. 14(4), no. January, pp. 2103–2109, 2020, doi: 10.1016/j.dsx.2020.10.022. Search in Google Scholar

14 G. Velinov, B. Jakimovski, D. Lesovski, D. Ivanova Panova, D. Frtunik, and M. Kon-Popovska, “EHR System MojTermin: Implementation and Initial Data Analysis,” Stud. Health Technol. Inform., vol. 210, pp. 872–876, 2015, doi: 10.3233/978-1-61499-512-8-872. Search in Google Scholar

15 C. Boodman, P. Lagacé-Wiens, and J. Bullard, “Diagnostic testing for SARSCoV-2,” CMAJ, vol. 192, no. 26, p. E713, 2020, doi: 10.1503/cmaj.200858. Search in Google Scholar

16 S. Ebrahim and M. Clarke, “STROBE: new standards for reporting observational epidemiology, a chance to improve,” Int. J. Epidemiol., vol. 36, no. 5, pp. 946–948, Oct. 2007, doi: 10.1093/ije/dym185. Search in Google Scholar

17 IBM, “IBM SPSS Advanced Statistics 24,” Ibm, 2016, doi: 10.1080/02331889108802322. Search in Google Scholar

18 P. Y. Chen and P. M. Popovich, “Correlation : parametric and nonparametric measures,” p. 95, 2002. Search in Google Scholar

19 A. Daher et al., “Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit,” Sci. Rep., vol. 11, no. 1, pp. 1–7, 2021, doi: 10.1038/s41598-021-81444-9. Search in Google Scholar

20 T. van der Veer et al., “Do-not-intubate status and COVID-19 mortality in patients admitted to Dutch non-ICU wards,” Eur. J. Clin. Microbiol. Infect. Dis., 2021, doi: 10.1007/s10096-021-04223-4. Search in Google Scholar

21 N. Pouw et al., “Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in the Netherlands: A retrospective cohort study,” PLoS One, vol. 16, no. 3 March, Mar. 2021, doi: 10.1371/journal.pone.0248713. Search in Google Scholar

22 B. Di and E. M. Glass, “The Kappa statistic: a second look,” Comput. Linguist., vol. 39, no. 1, pp. 95–101, 2004. Search in Google Scholar

23 A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, and G. Meyerowitz-Katz, “Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications,” Eur. J. Epidemiol., vol. 35, no. 12, pp. 1123–1138, Dec. 2020, doi: 10.1007/s10654-020-00698-1. Search in Google Scholar

24 B. G. Pijls et al., “Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies,” BMJ Open, vol. 11, no. 1, pp. 1–10, 2021, doi: 10.1136/bmjopen-2020-044640. Search in Google Scholar

25 M. S. Mohamed, T. C. Moulin, and H. B. Schiöth, “Sex differences in COVID-19: the role of androgens in disease severity and progression,” Endocrine, vol. 71, no. 1, p. 3, Jan. 2021, doi: 10.1007/S12020-020-02536-6. Search in Google Scholar

26 C. Huang et al., “Clinical Characteristics, Treatments and Outcomes of Critically Ill patients with COVID-19: A Scoping Review,” Mayo Clin. Proc., vol. 96, no. 1, pp. 183–202, 2021, doi: 10.1016/j.mayocp.2020.10.022. Search in Google Scholar

27 D. M. Smadja et al., COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects, vol. 24, no. 4. Springer Netherlands, 2021. Search in Google Scholar

28 S. Shibata et al., “Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19,” Hypertens. Res., vol. 43, no. 10, pp. 1028–1046, Oct. 2020, doi: 10.1038/s41440-020-0515-0. Search in Google Scholar

29 H. Zhang et al., “Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis,” J. Natl. Cancer Inst., vol. 113, no. 4, pp. 371–380, 2021, doi: 10.1093/jnci/djaa168. Search in Google Scholar

30 L. Kim, S. Garg, A. O’Halloran, and M. et al. Whitaker, “Risk Factors for intensive care unit admission and in-hospital mortality among hospitalized patients identified through the U.S. Coronavirus disease 2019 (COVID-10)-Associated Hospitalization Surveillance Network (COVID-NET),” BMJ Evidence-Based Med., 2020. Search in Google Scholar

31 I. Smokovski, T. Milenkovic, and N. H. Cho, “First stratified diabetes prevalence data for Republic of Macedonia derived from the National eHealth System,” Diabetes Res. Clin. Pract., vol. 143, no. 1, pp. 179–183, 2018, doi: 10.1016/j.diabres.2018.07.015. Search in Google Scholar

32 A. Kumar et al., “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis,” Diabetes Metab. Syndr., vol. 14, no. 4, p. 535, Jul. 2020, doi: 10.1016/J. DSX.2020.04.044. Search in Google Scholar

33 A. E. Mesas et al., “Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions,” PLoS One, vol. 15, no. 11 November, Nov. 2020, doi: 10.1371/journal.pone.0241742. Search in Google Scholar

34 L. Trajceska et al., “Excess mortality in a nephrology clinic during first months of corona-virus disease-19 pandemic: A pragmatic approach,” Open Access Maced. J. Med. Sci., vol. 8, no. T1, pp. 598–604, Dec. 2020, doi: 10.3889/OAMJMS.2020.5508. Search in Google Scholar

35 S. Pardhan, S. Wood, M. Vaughan, and M. Trott, “The Risk of COVID-19 Related Hospitalsation, Intensive Care Unit Admission and Mortality in People With Underlying Asthma or COPD: A Systematic Review and Meta-Analysis,” Front. Med., vol. 8, p. 853, Jun. 2021, doi: 10.3389/FMED.2021.668808/BIBTEX. Search in Google Scholar

36 W. W. Xiao, J. Xu, L. Shi, Y. D. Wang, and H. Y. Yang, “Is chronic obstructive pulmonary disease an independent predictor for adverse outcomes in coronavirus disease 2019 patients?,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 21. pp. 11421–11427, 2020, doi: 10.26355/eurrev_202011_23635. Search in Google Scholar

37 N. Rosenthal, Z. Cao, J. Gundrum, J. Sianis, and S. Safo, “Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19,” JAMA Netw. Open, vol. 3, no. 12, Dec. 2020, doi: 10.1001/JAMANETWORKOPEN.2020.29058. Search in Google Scholar

38 M. S. Marcolino, P. K. Ziegelmann, and M. V.. et al. Souza-Silva, “Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil : results from the Brazilian COVID-19 Registry,” Int. J. Infect. Dis., vol. 395, no. January, p. 1315, 2021, doi: 10.1016/j. ijid.2021.01.019. Search in Google Scholar

39 T. Brix, L. Hegedus, J. Hallas, and L. C. Lars, “Risk and course of SARS-COV-2 infection in patients treated for hypothyroidism and hyper-thyroidism,” Lancet Diabetes Endocrinol, 2021, doi: 10.1016/S2213-8587(21)00028-0. Search in Google Scholar